Thomas Collet is a serial life sciences entrepreneur with deep drug development expertise. He serves as President, CEO and Director of Bilayer Therapeutics. Dr. Collet has founded and led several life sciences companies including ProNAi Therapeutics (subsequently went public, now Sierra Oncology); Neural Intervention Technologies (subsequently acquired by W.L. Gore); and Rubicon Genomics (subsequently acquired by Takara Bio). He also served as Vice President of Business Development at Integrated Protein Technologies, a unit of Monsanto Company that Dr. Collet helped start. Prior to entering the start-up space, Dr. Collet served as General Partner at Tullis-Dickerson & Company, a healthcare focused venture fund, and as a consultant at McKinsey & Company. He earned a PhD in Biological Chemistry from the Massachusetts Institute of Technology and completed post-doctoral studies in Dr. Richard Lerner’s laboratory at The Scripps Research Institute.